Article

Clinical Trial: Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis

This clinical trial will determine if ketotifen/naphazoline is an effective treatment for acute allergic conjunctivitis.

Click here to access this third party resource:

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis

Study Type: Interventional

Age/Gender Requirements: 6 years+ (male/female)

Sponsor: Bausch & Lomb, Inc.

Purpose: To determine the safety and efficacy of ketotifen/naphazoline ophthalmic solution “compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.”

Related Videos
Diabetes Dialogue: Exploring New Horizons in Incretin Therapy for Diabetes and Weight Loss | Image Credit: HCPLive
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Christine Frissora, MD | Credit: Weill Cornell
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
4 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.